# Lenvatinib 24 mg/Day Versus 10 mg/Day to Treat Symptomatic or Progressive Radioactive Iodine Resistant (RAIR) Differentiated Thyroid Cancer (DTC)

> **NCT07092514** · PHASE2 · RECRUITING · sponsor: **Washington University School of Medicine** · enrollment: 34 (estimated)

## Conditions studied

- Thyroid Cancer
- Cancer of the Thyroid

## Interventions

- **DRUG:** Lenvatinib

## Key facts

- **NCT ID:** NCT07092514
- **Lead sponsor:** Washington University School of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-10-14
- **Primary completion:** 2029-04-17
- **Final completion:** 2034-10-31
- **Target enrollment:** 34 (ESTIMATED)
- **Last updated:** 2026-03-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07092514

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07092514, "Lenvatinib 24 mg/Day Versus 10 mg/Day to Treat Symptomatic or Progressive Radioactive Iodine Resistant (RAIR) Differentiated Thyroid Cancer (DTC)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07092514. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*